Research programme: antibacterial therapeutic - Hennepin Life Sciences
Alternative Names: AH2Latest Information Update: 28 Jul 2021
At a glance
- Originator Hennepin Life Sciences
- Class Anti-infectives; Antibacterials; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin and soft tissue infections
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in USA
- 22 Jun 2017 Preclinical trials in Skin and soft tissue infections in USA, before June 2017 (Hennepin Life Sciences website, June 2017)